Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB 18424-362 pancreatic cancer trial
2014-000293-20Phase 3Terminated
- Sponsor
- Incyte
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ruxolitinib in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Incyte. Primary endpoint: Overall survival. Started Jun 2014; status: terminated.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2014-000293-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000293-20.